Evaluation of the effects of a generic substitution policy implemented in Chile

Chile implemented a generic substitution policy in 2014 to improve access to medicines. This study aims to measure if the generic substitution policy had an effect on the sales volume and prices of referent and the branded generic products with demonstrated bioequivalence (BEQ) in the private pharmaceutical market. Overall, the volume of sales of the referent products decreased over time after the intervention. However, this reduction was not mirrored by an increase in the corresponding branded generic BEQ volumes overall. In all cases, the median price per DDD of the referent was higher than its BEQ counterpart in 2011 and 2016.

a:1:{i:0;s:43:"http://dx.doi.org/10.1136/bmjgh-2018-000922";}

Mansilla C, Cárdenas J, Kaplan WA, Wirtz VJ, Kuhn-Barrientos L, Ortíz de Zárate M. Evaluation of the effects of a generic substitution policy implemented in Chile. BMJ Global Health. 2019;2:e000922. doi: 10.1136/bmjgh-2018-000922